We are developing novel lipid based nanoparticles to deliver mRNA based therapies for the treatment of cystic fibrosis, retinal degeneration and against SARS-CoV2.
The long-term goal of our laboratory is to develop efficient non-viral vectors for intracellular delivery of nucleic acids.
Our focus is on three main research areas:
- to understand cellular trafficking of nanoparticles in-vivo and develop approaches to overcome endosomal barriers;
- to develop messenger (mRNA)-based gene therapy for the treatment of cystic fibrosis and eye disorders;
- to exploit supramolecular assembly of peptide-based nanomaterials for cell type specific delivery.